Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview

Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. Thi...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ahmed Ismail Eatmann, Esraa Hamouda, Heba Hamouda, Hossam Khaled Farouk, Afnan W. M. Jobran, Abdallah A. Omar, Alyaa Khaled Madeeh, Nada Mostafa Al-dardery, Salma Elnoamany, Eman Gamal Abd-Elnasser, Abdullah Muhammed Koraiem, Alhassan Ali Ahmed, Mohamed Abouzid, Marta Karaźniewicz-Łada
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2023-04-01
Saila:	Metabolites
Gaiak:	glioblastoma thalidomide antineoplastic agents angiogenesis chemotherapy VEGF
Sarrera elektronikoa:	https://www.mdpi.com/2218-1989/13/4/543
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!